Introduction
The model provides a comprehensive analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Analyze historical and forecast sales for all mAb products in the PharmaVitae universe
Assess all pipeline mAbs currently in development from pre-clinical testing to pre-registration
Other selected research from the 'Therapeutics' category:
Stakeholder Opinions: Biomarkers in Rheumatology - Awaiting the next step towards personalized medicine
The growing recognition from companies of the applied benefits from biomarkers in rheumatology has spurred commercial interest in this field. Despite the lack of major advancements, the hope remains that... Learn More
Stakeholder Opinions: Diabetic Renal Disease
In-depth analysis on the latest challenges, trends and developments in diagnosis, pharmacological and non- pharmacological treatment of Diabetic Renal Disease. Learn More
Other selected research from the 'Biologicals' category:
Competitor Analysis: BlyS, BAFF & APRIL Antagonists
Competitor Analysis: BlyS, BAFF & APRIL
Product description
The present Competitive Intelligence Report about BlyS, BAFF & APRIL Targeted Therapy provides a competitor evaluation in the field of molecules... Learn More
Product description
The present Competitive Intelligence Report about BlyS, BAFF & APRIL Targeted Therapy provides a competitor evaluation in the field of molecules... Learn More
Competitor Analysis: Biologic and Immune Therapy of S. aureus Infections
Biologic and Immune Therapy of S. aureus Infections
Product description
The present Competitive Intelligence Report about Biologic and Immuno Therapy of S. aureus Infections provides a competitor evaluation... Learn More
Product description
The present Competitive Intelligence Report about Biologic and Immuno Therapy of S. aureus Infections provides a competitor evaluation... Learn More